AllRock Bio Announces $50 Million Series A to Advance Lead Clinical Program for Pulmonary Hypertension
Summary
AllRock Bio raised $50 million in Series A financing to advance its lead drug candidate, ROC-101, for pulmonary arterial hypertension and interstitial lung disease-associated pulmonary hypertension. The company plans to move the program into Phase 2a testing and expects the ROCSTAR trial to begin in late 2025. Phase 1 results showed favorable safety and tolerability with no associated hypotension. AllRock also highlighted an experienced leadership team and its exclusive license to ROC-101 from Sanofi.
Funding
Amount
$50.0M
Total raised
Date
September 16, 2025
Announcement date
Investors
Versant Ventures, Merck, Westlake Village BioPartners, Alexion
Lead investors
Company
allrockbio.com
Funded company
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected